← SynDRA
SB-242235
SynDRA canonical compound SYN0003832 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | HSPB1 | MAPK14 |
|---|
| Mechanism of action | p38 MAPK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MAPK14 INHIBITOR
- HSPB1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABL1
- PHKG2
- NTRK2
- NTRK3
- PAK1
- PAK4
- PBK
- PDPK1
- PIM1
- NEK4
- PIM2
- PIM3
- PKN2
- PLK1
- PLK3
- PLK4
- NTRK1
- NEK2
- PRKACA
- MAPKAPK3
- MAPK1
- MAPK12
- MAPK13
- MAPK8
- MAPK9
- MAPKAPK2
- MAPKAPK5
- MKNK2
- MARK2
- MARK3
- MATK
- MELK
- MET
- MINK1
- PRKAA1
- PRKCA
- MAP4K4
- SRPK1
- RPS6KA5
- RPS6KB1
Cross-references
Synonyms
- SB 242235
- SB242235
- 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine
- CHEMBL95692
- 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine
- 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine
- Kinome_3169
- SCHEMBL2267209
- BDBM15458
- SYN1076
- PDTYLGXVBIWRIM-UHFFFAOYSA-N
- MolPort-028-720-427
- HMS3244I18
- HMS3244J17
- HMS3244I17
- EX-A1881
- BCP05992
- ZINC1487129
- 3254AH
- RS0056
- AKOS027323444
- CS-2097
- NCGC00345831-01
- NCGC00345831-03
- RefChem:931361
- C19H20FN5O
- MFCD08690575
- orb1303186
- GLXC-10732
- NCGC00345831-02
- AC-36230
- AS-16231
- FS101433
- HY-18306
- DB-065830
- SB242235?
- T4078
- BRD-K19412355-001-01-0
Look up SB-242235 in the interactive SynDRA portal →